tiprankstipranks
Advertisement
Advertisement

ADCT Stock Latest News

ADC Therapeutics Earnings Call: Trials, Cash And Risks
Company AnnouncementsADC Therapeutics Earnings Call: Trials, Cash And Risks
11d ago
ADCT
ADC Therapeutics: Strengthening Fundamentals, ZYNLONTA Pipeline Momentum, and Increased $8 Target Support Buy Rating
PremiumRatings
ADC Therapeutics: Strengthening Fundamentals, ZYNLONTA Pipeline Momentum, and Increased $8 Target Support Buy Rating
23d ago
ADCT
ADC Therapeutics price target raised to $8 from $7 at H.C. Wainwright
PremiumThe Fly
ADC Therapeutics price target raised to $8 from $7 at H.C. Wainwright
23d ago
ADCT
ADC Therapeutics files to sell 9.83M common shares for holders
PremiumThe Fly
ADC Therapeutics files to sell 9.83M common shares for holders
1M ago
ADCT
ADC Therapeutics reports Q4 adjusted EPS (9c), consensus (27c)
PremiumThe Fly
ADC Therapeutics reports Q4 adjusted EPS (9c), consensus (27c)
1M ago
ADCT
ADC Therapeutics sees cash runway at least into 2028
PremiumThe FlyADC Therapeutics sees cash runway at least into 2028
1M ago
ADCT
ADC Therapeutics Ltd (ADCT) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
ADC Therapeutics Ltd (ADCT) Q4 Earnings Cheat Sheet
1M ago
ADCT
ADC Therapeutics Amends Royalty Deal, Issues New Warrants
Premium
Company Announcements
ADC Therapeutics Amends Royalty Deal, Issues New Warrants
2M ago
8K
ADCT
ADC Therapeutics announces amended HealthCare Royalty financing agreement
PremiumThe Fly
ADC Therapeutics announces amended HealthCare Royalty financing agreement
2M ago
ADCT
ADC Therapeutics participates in a conference call with Cantor
PremiumThe Fly
ADC Therapeutics participates in a conference call with Cantor
2M ago
ADCT
ADC Therapeutics outlines ZYNLONTA-focused growth and financing strategy
PremiumCompany Announcements
ADC Therapeutics outlines ZYNLONTA-focused growth and financing strategy
3M ago
8K
ADCT
ADC Therapeutics Announces Preliminary 2025 Financial Results and Outlook
PremiumCompany Announcements
ADC Therapeutics Announces Preliminary 2025 Financial Results and Outlook
3M ago
8K
ADCT
ADC Therapeutics sees FY25 net product revenue $73M
PremiumThe FlyADC Therapeutics sees FY25 net product revenue $73M
3M ago
ADCT
ADC Therapeutics sees Q4 net product revenue $22M
Premium
The Fly
ADC Therapeutics sees Q4 net product revenue $22M
3M ago
ADCT
ADC Therapeutics Reports Promising LOTIS-7 Trial Results
Premium
Company Announcements
ADC Therapeutics Reports Promising LOTIS-7 Trial Results
4M ago
8K
ADCT
Promising LOTIS-7 Trial Results Reinforce Buy Rating for ADC Therapeutics
PremiumRatings
Promising LOTIS-7 Trial Results Reinforce Buy Rating for ADC Therapeutics
4M ago
ADCT
ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma
PremiumThe Fly
ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma
4M ago
ADCT
ADC Therapeutics: Strong Financials and Upcoming Trial Catalysts Support Buy Rating
PremiumRatings
ADC Therapeutics: Strong Financials and Upcoming Trial Catalysts Support Buy Rating
5M ago
ADCT
ADC Therapeutics Reports Q3 2025 Financial Results
PremiumCompany Announcements
ADC Therapeutics Reports Q3 2025 Financial Results
5M ago
ADCT
ADC Therapeutics Q3 2025 Earnings Call Highlights
PremiumCompany AnnouncementsADC Therapeutics Q3 2025 Earnings Call Highlights
5M ago
ADCT
ADC Therapeutics files to sell 14.7M common shares for holders
Premium
The Fly
ADC Therapeutics files to sell 14.7M common shares for holders
5M ago
ADCT
ADC Therapeutics reports Q3 adjsuted EPS (19c), consensus (36c)
Premium
The Fly
ADC Therapeutics reports Q3 adjsuted EPS (19c), consensus (36c)
5M ago
ADCT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >